

Urinary Protein Profile Changes in Diabetic Rats and Pre-diabetic Rats Fed with High Fat Diets

| | |
|----------------------|------------|
| Animal species | Rat |
| Condition Category | Diabetes |
| Date applied | 15-11-2019 |
| Date assigned | 20-11-2019 |
| Last edited | 21-11-2019 |
| Overall trial status | Completed |

SECTION A – PROJECT SUMMARY and PERSONNEL

A1 – PROJECT TITLE and SUMMARY

Project Title

This title will be used in all correspondence relating to this project

Urinary Protein Profile Changes in Diabetic Rats and Pre-diabetic Rats Fed with High Fat Diets

Project Summary

Provide a brief plain English snapshot of the project (max. 100 words).

This study aimed to analyze the changes in urinary protein profile in diabetic rats and pre-diabetic rats by the effect of HFD. Urine from ten groups of rats fed with different diet and metformin treatment was resolved by performing 1D electrophoresis. Results show that pre-diabetic rats with normal diet and metformin treatment are more like those of healthy rats with normal diet. This indicates that early metformin treatment, as well as diet control, is effective ways to delay the progression of pre-diabetes to diabetes.

A2 – PRINCIPAL RESEARCHER or PROJECT SUPERVISOR (*this is not the research student*)

Name (eg Dr John Smith)

Prof Gam Lay Harn

Qualifications relevant to this project

Corresponding Author

Mailing Address

School of Pharmaceutical Sciences,
Universiti Sains Malaysia,

11800 Minden,
Pulau Pinang

Work Phone No.

+604-6532208

Email Address

layharn@usm.my

ORCID ID

SECTION B – PROJECT DETAILS

| | | | | |
|-----------|---|---|-------------|--------------------|
| B1 | Duration of data collection for research | | | |
| | Start: | 01/11/2016 | End: | 01/07/2018 |
| B2 | Is this an ongoing OR completed protocol? | Ongoing | | Completed X |
| | If ONGOING, please indicate the date for completion | | | |
| B3 | Has the research been approved, or is it under consideration, by another Animal Ethics Committee (AEC)? | Yes | x | No |
| | Name of AEC: Animal Ethics Committee of Universiti Sains Malaysia | No. of approval letter: USM/Animal Ethics Approval /2016/(717) | | |

B4 List all the different types of animals to be used in this project.

| | |
|--------------------------------------|------------------------------------|
| Number of animals required: | 60 |
| Species Category No. & Name: | S2 - Rats - Laboratory |
| Common name of Species | Rat |
| Breed/Strain: | Sprague Dawley |
| Age: | 12 weeks |
| Sex: | Male |
| Source: | Animal Research Center, USM |
| Conservation status (if applicable): | |

Copy and paste this section again if more than one species is used

If the animal you are intending to conduct research on is not listed in the dropdown box, contact the Animal Ethics Secretary before proceeding further.

B5 Indicate from the list of **procedures** provided those that apply to this protocol (more than one may apply). Please **bold** the appropriate **number(s)** & **description(s)** in the list below:

| | | | |
|-----------|--|----|---|
| P1 | Observation involving minor interference | P6 | Minor physiological challenge |
| P2 | Animal unconscious without recovery | P7 | Major physiological challenge |
| P3 | Minor conscious intervention | P8 | Death as an end point i.e. LD50 or LC50 |

| | | | |
|----|-----------------------------|----|--|
| P4 | Minor surgery with recovery | P9 | Production of genetically modified animals |
| P5 | Major surgery with recovery | | |

B6 Indicate from the list of **purposes** provided those that apply to this protocol. Please **bold** the appropriate **number(s)** & **description(s)**:

| | | | |
|-----------|--|-----|---|
| A1 | Stock breeding | A6 | Research: Animal management or production |
| A2 | Stock maintenance | A7 | Research: Environmental study |
| A3 | Education | A8 | Production of biological products |
| A4 | Research: Human or animal biology | A9 | Diagnostic procedures |
| A5 | Research: Human or animal health & welfare | A10 | Regulatory product testing |

SECTION C – STUDY DESIGN

C1.1 A detailed description of the study design is crucial for preregistration

| | |
|--|--|
| Confirmatory studies | High fat diet was previously known to increase risk of type 2 diabetes by provoking insulin resistance and low-grade of systemic inflammation in the body. People living with type 2 diabetes are advised to follow a strict dietary plan to control the further progression of diabetes complications. Thus, diet management is one of the crucial steps in preventing diabetes prevalence. |
| Exploratory studies | This study is aimed to analyse the effect of high fat diet to the urinary protein profile of diabetic and prediabetic rats. |
| Method of blinding | None |
| Method of randomization | None |
| If no blinding and/or randomization will be applied, the reasons | No human studies included |

| | |
|--------------------------|--|
| should be briefly stated | |
|--------------------------|--|

C1.2. Methods

| | |
|--|--|
| Details of the apparatus | Metabolic Cage, Urine bottle, Oral Gavage Needle, Glucometer and glucose strips |
| Description of the consumables including the supplier | Sodium azide (Sigma, USA), Beddings (Chipsi, Italy), Glove (Gene Express, Malaysia), Syringe and needles (Terumo, Australia) |
| Software used for analysis | Quantity One (Biorad, USA), ImageLab (Biorad, USA) |
| Time of the day when the experiments will be conducted | 9 am – 12 pm |
| Measured parameters and their respective unit | Fasting Blood glucose level (mmol/L) |
| Previous handling or training of animals | YES |
| Method of euthanasia in case of ex vivo studies | NA |
| Details of the narcotic and/or analgesic treatment (e.g., preanesthetic treatment, type of anesthesia including the name of drugs and substances) | NA |
| Details of the drugs and substances being used including, e.g., name of the supplier, route of administration, dosing, treatment intervals, duration and time point of the treatment | Metformin 500mg (Dynapharm, Malaysia), |
| Provision of the suppliers' name and catalog number if antibodies will be used | NA |

| | |
|--|----|
| A list of all cell lines, viruses, DNA or RNA constructs, and bacteria that will be used | NA |
|--|----|

C1.3. Statistics

| | |
|---|---|
| The main experimental endpoints the sample size calculation relies on | 6 weeks of Dietary treatment |
| A sample size calculation | 10 groups 6 animals per group, $10 \times 6 = 60$ |
| Any additional outcomes measures that will be assessed | NA |
| What kind of primary statistical analysis will be used | NA |
| Exclusion criteria for certain data points if applicable | NA |